Platinum-based drugs: past, present and future
- PMID: 26886018
- DOI: 10.1007/s00280-016-2976-z
Platinum-based drugs: past, present and future
Abstract
Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of human neoplasms. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Much effort has been put into the development of new platinum anticancer complexes, but none of them has reached worldwide clinical application so far. Nedaplatin, lobaplatin and heptaplatin received only regional approval. Some new platinum complexes and platinum drug formulations are undergoing clinical trials. Here, we review the main classes of new platinum drug candidates, such as sterically hindered complexes, monofunctional platinum drugs, complexes with biologically active ligands, trans-configured and polynuclear platinum complexes, platinum(IV) prodrugs and platinum-based drug delivery systems. For each class of compounds, a detailed overview of the mechanism of action is given, the cytotoxicity is compared to that of the clinically used platinum drugs, and the clinical perspectives are discussed. A critical analysis of lessons to be learned is presented. Finally, a general outlook regarding future directions in the field of new platinum drugs is given.
Keywords: Clinical perspective; Future directions; Platinum drugs; Resistance; Toxicity.
Similar articles
-
Fresh platinum complexes with promising antitumor activity.Anticancer Agents Med Chem. 2010 Jun;10(5):396-411. doi: 10.2174/1871520611009050396. Anticancer Agents Med Chem. 2010. PMID: 20545618 Review.
-
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.J Inorg Biochem. 1999 Oct;77(1-2):111-5. J Inorg Biochem. 1999. PMID: 10626362 Review.
-
The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.Curr Med Chem. 2009;16(18):2235-60. doi: 10.2174/092986709788453087. Curr Med Chem. 2009. PMID: 19519389 Review.
-
Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action.J Inorg Biochem. 2020 Jun;207:111070. doi: 10.1016/j.jinorgbio.2020.111070. Epub 2020 Mar 23. J Inorg Biochem. 2020. PMID: 32299045 Review.
-
The Platin-X series: activation, targeting, and delivery.Dalton Trans. 2016 Aug 16;45(33):12992-3004. doi: 10.1039/c6dt01738j. Dalton Trans. 2016. PMID: 27493131 Free PMC article. Review.
Cited by
-
Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.Chem Res Toxicol. 2016 Dec 19;29(12):1976-1986. doi: 10.1021/acs.chemrestox.6b00234. Epub 2016 Oct 11. Chem Res Toxicol. 2016. PMID: 27726383 Free PMC article. Review.
-
DNA Damage Promotes Epithelial Hyperplasia and Fate Mis-specification via Fibroblast Inflammasome Activation.Dev Cell. 2020 Dec 7;55(5):558-573.e6. doi: 10.1016/j.devcel.2020.09.021. Epub 2020 Oct 14. Dev Cell. 2020. PMID: 33058780 Free PMC article.
-
Design, Synthesis, Electrochemical, and Biological Evaluation of Fluorescent Chlorido[N,N'-bis(methoxy/hydroxy)salicylidene-1,2-bis(4-methoxyphenyl)ethylenediamine]iron(III) Complexes as Anticancer Agents.J Med Chem. 2023 Dec 14;66(23):15916-15925. doi: 10.1021/acs.jmedchem.3c01359. Epub 2023 Nov 27. J Med Chem. 2023. PMID: 38013413 Free PMC article.
-
Platinum Complexes in Colorectal Cancer and Other Solid Tumors.Cancers (Basel). 2021 Apr 25;13(9):2073. doi: 10.3390/cancers13092073. Cancers (Basel). 2021. PMID: 33922989 Free PMC article. Review.
-
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.Cancers (Basel). 2020 Oct 5;12(10):2863. doi: 10.3390/cancers12102863. Cancers (Basel). 2020. PMID: 33027952 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous